Neovacs
Biotech firm developing immunotherapies and investing in BioTech and MedTech.
ALNEV | Euronext Growth
Overview
Corporate Details
- ISIN(s):
- FR0004032746 (+4 more)
- LEI:
- 9695001J9GMM5XYK6482
- Country:
- France
- Address:
- 14 RUE DE LA REPUBLIQUE, 92150 SURESNES
- Website:
- https://www.neovacs.com/en/
Description
Neovacs is a biotechnology company with two main activities: research and development, and investment. The company's R&D focuses on its proprietary Kinoid technology platform, an active immunotherapy approach for treating autoimmune diseases and allergies. This technology develops therapeutic vaccines designed to stimulate the patient's immune system to regulate the overproduction of harmful cytokines. Key indications for its Kinoid products include lupus. In addition to its internal development, Neovacs invests in high-potential BioTech and MedTech companies, leveraging its experienced team to evaluate and support innovative products and medical devices.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-08-29 08:00 |
Le CNRS met à l'honneur Néovacs et l'UTCBS, unis pour un vaccin thérapeutique à…
|
French | 221.7 KB | ||
| 2024-08-28 23:00 |
Ajustement de la valeur nominale
|
French | 213.2 KB | ||
| 2024-08-08 18:30 |
Information relative au nombre total de droits de vote et d'actions composant l…
|
French | 287.6 KB | ||
| 2024-07-30 18:30 |
Levée de fonds de 0,2 MEUR
|
French | 235.3 KB | ||
| 2024-07-04 20:00 |
Résiliation du contrat de financement accordé à Pharnext
|
French | 216.8 KB | ||
| 2024-07-03 08:00 |
Décisions du Conseil d'administration du 2 juillet 2024
|
French | 213.6 KB | ||
| 2024-06-28 08:00 |
Décisions du Conseil d'administration du 27 juin 2024
|
French | 217.4 KB | ||
| 2024-06-17 08:00 |
Néovacs signe un accord de collaboration avec le CNRS sur la mise au point de n…
|
French | 229.0 KB | ||
| 2024-06-12 18:00 |
NEOVACS convoque à nouveau ses actionnaires en assemblée générale le 27 juin 20…
|
French | 222.3 KB | ||
| 2024-06-10 08:00 |
Néovacs a présenté les derniers résultats de ses candidats-vaccins ciblant les …
|
French | 239.3 KB | ||
| 2024-06-04 18:00 |
Levée de fonds de 0,2 MEUR
|
French | 233.4 KB | ||
| 2024-05-29 08:00 |
Supériorité du vaccin à ARNm en traitement des allergies chez le primate non hu…
|
French | 214.5 KB | ||
| 2024-05-27 08:00 |
Néovacs signe un accord de collaboration avec l'INSERM sur la mise au point d'u…
|
French | 232.8 KB | ||
| 2024-05-06 18:00 |
NEOVACS convoque ses actionnaires en assemblée générale le 10 juin 2024
|
French | 225.5 KB | ||
| 2024-05-02 18:00 |
Information relative au nombre total de droits de vote et d'actions composant l…
|
French | 241.0 KB |
Automate Your Workflow. Get a real-time feed of all Neovacs filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Neovacs
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Neovacs via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
